Trevi Therapeutics, Inc., a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, has announced a Series B financing of $25 million.
Trevi plans to use the funding for the initiation of pivotal trials in two severe itch conditions: uremic pruritus and prurigo nodularis. The company recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was shown to be well tolerated in patients on hemodialysis with itch and established proof-of-concept in uremic pruritus.

“We continue to believe that the dual mechanism of action of nalbuphine is uniquely suited to treating many itch conditions,” said Jennifer L. Good, Trevi’s president and CEO.